Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is enrolling by invitation. It plans to enroll 900 participants.
Also called NCT04848506
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 900 participants
- Sponsor
- Registry
-
NCT04848506 -
2020-003571-17
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Australia, Brazil, Canada, Czechia, Denmark, France, Germany, Greece, Hungary, Iceland, Israel, Italy, Netherlands, Poland, Portugal, Spain, United Kingdom
- Registry status
- Enrolling by invitation
Technical summary
Registry record NCT04848506. Allocation not applicable; no masking; primary purpose treatment. Start 2021-05-06 (actual); primary completion 2029-03 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of Aficamten in Adults With HCM
- Acronym
- FOREST-HCM
- Condition
- Symptomatic Hypertrophic Cardiomyopathy (HCM)
- Intervention (Drug)
- Aficamten (5 - 20 mg)
- Lead sponsor
- Cytokinetics
Record details
- Record id
cardio:ct-nct04848506- Content hash
df6a85e83f0b7d4b3a9f921494736b695b719c30168063f5f53932950ea4be85